Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15935 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Behnam Noorani und 8 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie, Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Renal Insufficiency, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: AbbVie, Genentech.
Abstract (Originalsprache)
Aims
Renal insufficiency is a common comorbidity in patients with haematological malignancies. This study aimed to assess how end‐stage renal disease (ESRD) might affect the pharmacokinetics of venetoclax, a Bcl‐2 inhibitor, in participants with ESRD undergoing haemodialysis.
Methods
Venetoclax was administered as a single 100‐mg dose to 6 female participants with ESRD (estimated glomerular filtration rate 90 mL/min). Intensive pharmacokinetic and protein binding samples were collected from all participants. Arterial and venous samples were collected from ESRD participants during haemodialysis to assess the effect of haemodialysis on venetoclax pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods.
Results
There was no difference in plasma venetoclax concentrations between arterial and venous samples, suggesting that haemodialysis did not affect the pharmacokinetics of venetoclax. The fraction unbound ( f u ) of venetoclax was ~2‐fold higher for participants with ESRD compared to participants with normal renal function. The unbound maximum plasma concentration and area under the plasma concentration–time curve from time 0 to 48 h were comparable between ESRD and normal function groups. The mean half‐life ranged from 10.4 to 12.2 h across groups, demonstrating that ESRD did not affect the half‐life of venetoclax. No new safety signals were observed during this study.
Conclusion
ESRD and dialysis do not alter unbound venetoclax plasma concentrations. No pharmacokinetics driven dose adjustment is needed for patients with renal insufficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AbbVie, Inc., North Chicago, Illinois, USA.
- Genentech Inc., South San Francisco, California, USA.
- Pharmacyclics, an AbbVie company in Switzerland, Schaffhausen, Switzerland.
- Orlando Clinical Research Center, Orlando, Florida, USA.
- Clinical Pharmacy, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Behnam Noorani, Rajeev M Menon, Thomas Marbury, Ahmed Hamed Salem
Förderung
- AbbVie
- Genentech
Zitieren
APA
Noorani, B., Menon, R. M., Chen, X., Marsh, K. C., Huang, W., Gupta, S., Dobkowska, E., Marbury, T., & Salem, A. H. (2024). Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15935
Vancouver
Noorani B, Menon RM, Chen X, Marsh KC, Huang W, Gupta S, et al. Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15935
BibTeX
@article{Noorani2024,
author = {Noorani, Behnam and Menon, Rajeev M and Chen, Xin and Marsh, Kennan C and Huang, Weize and Gupta, Shelly and Dobkowska, Edyta and Marbury, Thomas and Salem, Ahmed Hamed},
title = {Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15935}
}
EUVIMED